AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm Female
Interventions: DRUG: AK105|DRUG: Anlotinib hydrochloride|DRUG: Albumin Paclitaxel
Sponsor: Liaoning Tumor Hospital & Institute
Collaborators: Huludao central hospital|Anshan Tumor Hospital|Chaoyang Central Hospital|Fukuang General Hospital of Liaoning health industry group